 | • レポートコード：360iR22DE028 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、244ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査報告書では、2021年に835.85百万ドルであった世界の乳房生検市場規模が、2022年に917.23百万ドルになり、2027年まで年平均9.91%で成長して1,473.75百万ドルに達すると予測しています。本報告書では、乳房生検の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（リキッド乳房生検、ニードル乳房生検、開胸外科的乳房生検）分析、ガイダンス別（画像誘導下乳房生検、リキッド乳房生検）分析、用途別（早期がん検診、再発モニタリング、治療法選択、治療モニタリング）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の項目を掲載しています。本書に記載されている企業情報としては、Argon Medical Devices, Inc.、Becton, Dickinson and Company、Bio-Rad Laboratories, Inc.、Biocept, Inc.、Cardiff Oncology, Inc.、Cook Medical Incorporated、Danaher Corporation、Encapsule Medical Devices, LLC、Ethicon Endo-Surgeryなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の乳房生検市場規模：種類別 - リキッド乳房生検の市場規模 - ニードル乳房生検の市場規模 - 開胸外科的乳房生検の市場規模 ・世界の乳房生検市場規模：ガイダンス別 - 画像誘導下乳房生検の市場規模 - リキッド乳房生検の市場規模 ・世界の乳房生検市場規模：用途別 - 早期がん検診における市場規模 - 再発モニタリングにおける市場規模 - 治療法選択における市場規模 - 治療モニタリングにおける市場規模 ・世界の乳房生検市場規模：地域別 - 南北アメリカの乳房生検市場規模 アメリカの乳房生検市場規模 カナダの乳房生検市場規模 ブラジルの乳房生検市場規模 … - アジア太平洋の乳房生検市場規模 日本の乳房生検市場規模 中国の乳房生検市場規模 インドの乳房生検市場規模 韓国の乳房生検市場規模 台湾の乳房生検市場規模 … - ヨーロッパ/中東/アフリカの乳房生検市場規模 イギリスの乳房生検市場規模 ドイツの乳房生検市場規模 フランスの乳房生検市場規模 ロシアの乳房生検市場規模 … - その他地域の乳房生検市場規模 ・競争状況 ・企業情報 |
The Global Breast Biopsy Market size was estimated at USD 835.85 million in 2021 and expected to reach USD 917.23 million in 2022, and is projected to grow at a CAGR 9.91% to reach USD 1,473.75 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Breast Biopsy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Assay Kits, Biopsy Needles, Biopsy Tables, Guidance Systems, Liquid Biopsy Instruments, and Localization Wires.
Based on Type, the market was studied across Liquid Breast Biopsy, Needle Breast Biopsy, and Open Surgical Breast Biopsy. The Liquid Breast Biopsy is further studied across Circulating Tumor Cells and Circulating Tumor DNA. The Needle Breast Biopsy is further studied across Core Needle Biopsy, Fine Needle Aspiration Biopsy, and Vacuum-Assisted Biopsy. The Open Surgical Breast Biopsy is further studied across Excisional and Incisional.
Based on Guidance, the market was studied across Image-Guided Biopsy and Liquid Biopsy. The Image-Guided Biopsy is further studied across Mammography-Guided Stereotactic Biopsy, MRI Guided Biopsy, and Ultrasound-Guided Biopsy. The Liquid Biopsy is further studied across Microarray-Based Biopsy, NGS-Based Biopsy, and PCR-Based Biopsy.
Based on Application, the market was studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Breast Biopsy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Biopsy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Biopsy Market, including Argon Medical Devices, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Cardiff Oncology, Inc., Cook Medical Incorporated, Danaher Corporation, Encapsule Medical Devices, LLC, Ethicon Endo-Surgery, EXACT Sciences Corporation, F. Hoffmann-La Roche AG, Fluxion Biosciences, Inc., Gallini S.r.l., Hologic, Inc., Illumina, Inc., IZI Medical Products, LLC, Leica Biosystems Nussloch GmbH, Medtronic PLC, Menarini Silicon Biosystems, S.p.A., Merit Medical Systems, Inc., Myriad Genetics, Inc., QIAGEN, Scion Medical Technologies, LLC, STERYLAB S.r.l., and Thermo Fisher Scientific.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Breast Biopsy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Biopsy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Biopsy Market?
4. What is the competitive strategic window for opportunities in the Global Breast Biopsy Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Biopsy Market?
6. What is the market share of the leading vendors in the Global Breast Biopsy Market?
7. What modes and strategic moves are considered suitable for entering the Global Breast Biopsy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising concerns of breast cancer screening programs
5.1.1.2. Growing awareness regarding early detection of breast cancer
5.1.2. Restraints
5.1.2.1. Infectious risk associated with breast biopsy procedures
5.1.2.2. Stringent regulatory approval policies
5.1.3. Opportunities
5.1.3.1. Emergence of liquid biopsy and promising clinical trials
5.1.3.2. Increasing investments and funding for R&D of cancer treatment
5.1.4. Challenges
5.1.4.1. Dearth of skilled persons and costly treatment
5.1.4.2. Lack of advance infrastructure in developing countries
5.2. Cumulative Impact of COVID-19
6. Breast Biopsy Market, by Product
6.1. Introduction
6.2. Assay Kits
6.3. Biopsy Needles
6.4. Biopsy Tables
6.5. Guidance Systems
6.6. Liquid Biopsy Instruments
6.7. Localization Wires
7. Breast Biopsy Market, by Type
7.1. Introduction
7.2. Liquid Breast Biopsy
7.3.1. Circulating Tumor Cells
7.3.2. Circulating Tumor DNA
7.3. Needle Breast Biopsy
7.4.1. Core Needle Biopsy
7.4.2. Fine Needle Aspiration Biopsy
7.4.3. Vacuum-Assisted Biopsy
7.4. Open Surgical Breast Biopsy
7.5.1. Excisional
7.5.2. Incisional
8. Breast Biopsy Market, by Guidance
8.1. Introduction
8.2. Image-Guided Biopsy
8.3.1. Mammography-Guided Stereotactic Biopsy
8.3.2. MRI Guided Biopsy
8.3.3. Ultrasound-Guided Biopsy
8.3. Liquid Biopsy
8.4.1. Microarray-Based Biopsy
8.4.2. NGS-Based Biopsy
8.4.3. PCR-Based Biopsy
9. Breast Biopsy Market, by Application
9.1. Introduction
9.2. Early Cancer Screening
9.3. Recurrence Monitoring
9.4. Therapy Selection
9.5. Treatment Monitoring
10. Americas Breast Biopsy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Breast Biopsy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Breast Biopsy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Argon Medical Devices, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Becton, Dickinson and Company
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Bio-Rad Laboratories, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Biocept, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Cardiff Oncology, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Cook Medical Incorporated
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Danaher Corporation
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Encapsule Medical Devices, LLC
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Ethicon Endo-Surgery
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. EXACT Sciences Corporation
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. F. Hoffmann-La Roche AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Fluxion Biosciences, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Gallini S.r.l.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Hologic, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Illumina, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. IZI Medical Products, LLC
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Leica Biosystems Nussloch GmbH
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Medtronic PLC
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Menarini Silicon Biosystems, S.p.A.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Merit Medical Systems, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Myriad Genetics, Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. QIAGEN
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Scion Medical Technologies, LLC
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. STERYLAB S.r.l.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Thermo Fisher Scientific
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing